NeoGenomics Laboratories - רווח נקי למניה אחת בשנים עשר החודשים האחרונים NEO

IT pipeline automation and the procurement of sequencers are boosting margins for NeoGenomics, Inc. (NEO), as evidenced by the historical year-over-year EPS growth (TTM). Premium pricing in oncogenetics strengthens the company's position, while centralized hubs reduce unit costs. Meanwhile, 72.20 represents the latest metric reading, allowing for the filtering of market noise to assess the business's actual annual profitability.
NEO (NeoGenomics Laboratories): פילוחים אנליטיים ודוחות לפי אינדיקטורים

As a leader in oncology testing with inelastic demand, NeoGenomics, Inc. (NEO) ensures high profit predictability, making earnings per share dynamics a key performance indicator. This metric measures the percentage change in EPS over the last twelve months, allowing for an assessment of business scaling rates and the quality of capital management through the current state of annual EPS TTM growth.